Work

Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Year: 2020

Type: article

Study design: Study Protocol

Source: Blood

DOI: 10.1182/blood-2020-139022

Authors: Meghan C. Thompson, Matthew S. Davids, Nitin Jain, Jacob D. Soumerai, Praveen Ramakrishnan Geethakumari, Amy Gubits, Denice Hickman, Anders Wennborg, Eyal C. Attar, Omar Abdel-Wahab, Anthony R. Mato

Institutions: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, The University of Texas Southwestern Medical Center, Aprea Therapeutics, Inc. (United States)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3096319450

FWCI: 0.128

Cites:

Cited by: 2

Related to: 10